Trump's Small Financial Stake in Hydroxychloroquine Maker

Headline Roundup April 7th, 2020

On Monday, the New York Times reported that President Donald Trump has financial ties to a company that manufactures the anti-malaria drug hydroxychloroquine, which the president has said could be a potential treatment for the COVID-19 coronavirus. There is no known cure for COVID-19.

Most outlets, regardless of rating, reported that the president's stake in Sanofi is relatively small, amounting to $3,000 or less. Some left-rated outlets framed the president's touting of hydroxychloroquine as an attempt to use his political platform to further his personal financial interests. Trump is the second wealthiest elected U.S. official, behind Illinois Governor J.B. Pritzker.

Trump's Small Financial Stake in Hydroxychloroquine Maker

From the Left
12553

President Donald Trump has been raising questions by his dogged endorsement of an unproven treatment for the coronavirus — and his motivations appear to be more financial than medical.

Trump admits he’s not a doctor — which, of course, he’s not — but MSNBC’s Joe Scarborough and the Washington Post‘s Eugene Robinson are among many wondering whether the president is trying to boost the market for the antimalarial drug hydroxychloroquine.

“As ‘Deep Throat’ never actually said, follow the money,” Robinson said, quoting the apocryphal advice from the undercover source who...

Read full story
From the Center
12553
ANALYSIS

Topline: President Trump—increasingly a booster of hydroxychloroquine as a potential treatment for coronavirus—has a “small personal financial interest” in Sanofi, a French drugmaker that produces a brand-name version of the drug—though it’s a tiny investment for the billionaire.

Sanofi produces Plaquenil, the brand-name form of hydroxychloroquine, the New York Times reported; the drug is typically used to treat rheumatoid arthritis, lupus and malaria.
Trump’s three family trusts have investments in a Dodge & Cox mutual fund, with Sanofi as the largest holding, according to the Times.
Forbes estimates...

Read full story
From the Right
12553

As President Donald Trump has persistently discussed the malaria drug hydroxychloroquine, critics have wondered about his motivation, given the drug’s far-from-certain performance on the global stage as a treatment for coronavirus, and the Food and Drug Administration’s refusal so far to approve it as a treatment for COVID-19.

The New York Times says Trump has a “small personal stake” in Sanofi, the French drug manufacturer that produces the drug.

The report doesn’t say how small, but it notes that his three family trusts have investments in a Dodge & Cox...

Read full story